Hydroxyurea use in young infants with sickle cell disease.

Area of Science:

• Hematology
• Pediatric Medicine
• Pharmacology

Background:

• Hydroxyurea (HU) is a proven treatment for sickle cell disease (SCD), reducing complications and improving patient survival.
• Existing evidence suggests initiating HU therapy after nine months of age.

Purpose of the Study:

• To evaluate the safety and efficacy of initiating hydroxyurea (HU) therapy in pediatric patients with sickle cell disease (SCD) at different early age groups.
• To compare clinical outcomes, laboratory data, and toxicity profiles among infants and young children starting HU treatment before five years of age.

Main Methods:

• A retrospective study analyzed 65 pediatric patients with SCD who began HU treatment between 2008 and 2016.
• Patients were divided into three cohorts based on age at HU initiation: 0-1 year (cohort 1), 1-2 years (cohort 2), and 2-5 years (cohort 3).
• Clinical events, laboratory values, and treatment toxicity were assessed and compared across the three age cohorts.

Main Results:

• Cohort 1 (0-1 year) exhibited higher hemoglobin and MCV, and lower absolute reticulocyte count and absolute neutrophil count (ANC) at 24 months compared to cohort 3 (2-5 years).
• Baseline and sustained Hemoglobin F (HbF) levels were significantly higher in cohort 1 compared to older cohorts.
• Cohort 1 experienced fewer hospitalizations and transfusions, with no significant difference in toxicity observed across groups.

Conclusions:

• Hydroxyurea (HU) is safe and effective when initiated in infants aged 5 to 12 months with sickle cell disease (SCD).
• Starting HU therapy earlier, specifically in the 5-12 month age range, generates a more robust therapeutic response compared to initiation in older children.
• Early intervention with HU in SCD patients demonstrates improved clinical outcomes and sustained efficacy.